Jim Simons
ESPR

Jim Simons’s Esperion Therapeutics ESPR Stock Holding History

Jim Simons’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$506K Sell
160,200
-1,459,900
-90% -$4.08M ﹤0.01% 2608
2026
Q1 		$4.44M Sell
1,620,100
-574,500
-26% -$1.82M 0.01% 1444
2025
Q4 		$8.12M Buy
2,194,600
+1,420,700
+184% +$4.59M 0.01% 1028
2025
Q3 		$2.05M Buy
773,900
+481,500
+165% +$931K ﹤0.01% 2054
2025
Q2 		$288K Buy
+292,400
New +$293K ﹤0.01% 3056
2025
Q1 		– Sell
-578,800
Closed -$1.27M – 3560
2024
Q4 		$1.27M Sell
578,800
-335,300
-37% -$782K ﹤0.01% 2345
2024
Q3 		$1.51M Sell
914,100
-507,800
-36% -$1.03M ﹤0.01% 2198
2024
Q2 		$3.16M Sell
1,421,900
-694,600
-33% -$1.63M 0.01% 1586
2024
Q1 		$5.67M Buy
2,116,500
+696,400
+49% +$1.69M 0.01% 1338
2023
Q4 		$4.25M Buy
1,420,100
+1,213,944
+589% +$1.57M 0.01% 1454
2023
Q3 		$202K Buy
206,156
+91,856
+80% +$133K ﹤0.01% 3090
2023
Q2 		$159K Buy
+114,300
New +$160K ﹤0.01% 3341
2022
Q4 		– Sell
-286,700
Closed -$1.92M – 4183
2022
Q3 		$1.92M Sell
286,700
-98,600
-26% -$677K ﹤0.01% 2042
2022
Q2 		$2.45M Sell
385,300
-36,900
-9% -$209K ﹤0.01% 2039
2022
Q1 		$1.96M Buy
+422,200
New +$1.81M ﹤0.01% 2245
2019
Q4 		– Sell
-141,900
Closed -$5.2M – 3558
2019
Q3 		$5.2M Sell
141,900
-95,600
-40% -$3.79M ﹤0.01% 1770
2019
Q2 		$11M Buy
237,500
+41,905
+21% +$1.97M 0.01% 1334
2019
Q1 		$7.85M Buy
195,595
+177,695
+993% +$7.97M 0.01% 1512
2018
Q4 		$823K Buy
+17,900
New +$862K ﹤0.01% 2668
2017
Q4 		– Sell
-14,500
Closed -$727K – 3378
2017
Q3 		$727K Buy
+14,500
New +$699K ﹤0.01% 2685
2016
Q4 		– Sell
-318,800
Closed -$4.42M – 3297
2016
Q3 		$4.42M Buy
+318,800
New +$3.61M 0.01% 1683
2016
Q2 		– Sell
-107,600
Closed -$1.82M – 3374
2016
Q1 		$1.82M Sell
107,600
-253,600
-70% -$4.08M ﹤0.01% 2279
2015
Q4 		$8.04M Buy
+361,200
New +$9.11M 0.02% 1140

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jim Simons's ESPR Position: Q2 2026 in Review

Jim Simons reduced its Esperion Therapeutics (ESPR) stake by 90% in Q2 2026, selling an estimated $4.08M and leaving 160,200 shares worth $506K. The position accounts for ﹤0.01% of the portfolio, ranked #2608.

Jim Simons first reported a position in ESPR in Q4 2015 and has held it in 23 quarters since. The position peaked at $11M in Q2 2019. 130 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Jim Simons held 160,200 shares of Esperion Therapeutics worth $506K as of Q2 2026.
  • Jim Simons sold 1,459,900 Esperion Therapeutics shares in Q2 2026, an estimated $4.08M.
  • Esperion Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2608 holding.
  • Jim Simons first reported a position in Esperion Therapeutics in Q4 2015 and has held it in 23 quarters since.
  • Jim Simons's Esperion Therapeutics position peaked at $11M in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.